Loading...

Compugen

Nasdaq:CGEN
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CGEN
Nasdaq
$207M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
CGEN Share Price and Events
7 Day Returns
-0.9%
NasdaqGM:CGEN
-2.9%
US Life Sciences
-0.7%
US Market
1 Year Returns
9.8%
NasdaqGM:CGEN
20.3%
US Life Sciences
3%
US Market
CGEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Compugen (CGEN) -0.9% 2.1% -1.1% 9.8% -49.9% -58.2%
US Life Sciences -2.9% -4.1% -1% 20.3% 79.3% 106.4%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • CGEN underperformed the Life Sciences industry which returned 20.3% over the past year.
  • CGEN outperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
CGEN
Industry
5yr Volatility vs Market

Value

 Is Compugen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Compugen. This is due to cash flow or dividend data being unavailable. The share price is $3.46.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Compugen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Compugen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CGEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.41
NasdaqGM:CGEN Share Price ** NasdaqGM (2019-05-17) in USD $3.46
United States of America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 33.93x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Compugen.

NasdaqGM:CGEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CGEN Share Price ÷ EPS (both in USD)

= 3.46 ÷ -0.41

-8.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Compugen is loss making, we can't compare its value to the US Life Sciences industry average.
  • Compugen is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Compugen's expected growth come at a high price?
Raw Data
NasdaqGM:CGEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-8.9%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 2.34x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Compugen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Compugen's assets?
Raw Data
NasdaqGM:CGEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.62
NasdaqGM:CGEN Share Price * NasdaqGM (2019-05-17) in USD $3.46
United States of America Life Sciences Industry PB Ratio Median Figure of 37 Publicly-Listed Life Sciences Companies 4.59x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGM:CGEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CGEN Share Price ÷ Book Value per Share (both in USD)

= 3.46 ÷ 0.62

5.56x

* Primary Listing of Compugen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Compugen is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Compugen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Compugen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Compugen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Compugen expected to grow at an attractive rate?
  • Unable to compare Compugen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Compugen's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Compugen's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CGEN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CGEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -8.9%
NasdaqGM:CGEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -12.6%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CGEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CGEN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 12 -43 -43 1
2022-12-31 0 -37 -41 2
2021-12-31 0 -33 -37 2
2020-12-31 0 -27 -32 2
2019-12-31 0 -32 -36 2
NasdaqGM:CGEN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 18 -13 -23
2018-09-30 18 -23
2018-06-30 10 -23 -29
2018-03-31 10 -28
2017-12-31 -31 -37
2017-09-30 0 -36
2017-06-30 0 -27 -34
2017-03-31 1 -32
2016-12-31 1 -20 -32
2016-09-30 9 -23
2016-06-30 9 -20 -22
2016-03-31 9 -23

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Compugen is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Compugen's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CGEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Compugen Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CGEN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.62 -0.41 -0.83 2.00
2022-12-31 -0.59 -0.46 -0.72 2.00
2021-12-31 -0.53 -0.44 -0.62 2.00
2020-12-31 -0.50 -0.47 -0.52 2.00
2019-12-31 -0.58 -0.58 -0.58 2.00
NasdaqGM:CGEN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.41
2018-09-30 -0.42
2018-06-30 -0.57
2018-03-31 -0.55
2017-12-31 -0.72
2017-09-30 -0.71
2017-06-30 -0.67
2017-03-31 -0.62
2016-12-31 -0.62
2016-09-30 -0.46
2016-06-30 -0.44
2016-03-31 -0.45

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Compugen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Compugen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Compugen has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Compugen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Compugen's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Compugen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Compugen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Compugen's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Compugen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Compugen Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CGEN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 17.80 -22.60 9.68 30.32
2018-09-30 17.80 -22.51 9.68 30.02
2018-06-30 10.00 -29.27 9.35 29.89
2018-03-31 10.00 -28.26 9.24 28.92
2017-12-31 -37.07 8.82 28.58
2017-09-30 0.05 -36.25 9.05 27.72
2017-06-30 0.12 -34.16 8.71 26.11
2017-03-31 0.62 -31.61 8.47 24.51
2016-12-31 0.71 -31.51 8.52 24.55
2016-09-30 8.97 -23.49 8.28 24.04
2016-06-30 9.13 -22.45 7.88 23.37
2016-03-31 8.86 -22.62 7.76 23.23
2015-12-31 9.28 -20.16 7.32 21.25
2015-09-30 7.52 -21.17 6.95 20.29
2015-06-30 9.01 -19.83 7.00 18.87
2015-03-31 10.75 -15.34 6.51 16.62
2014-12-31 12.37 -11.09 6.29 15.07
2014-09-30 7.59 -12.54 6.12 13.48
2014-06-30 7.46 -11.89 6.15 12.42
2014-03-31 5.52 -12.61 6.02 12.78
2013-12-31 3.55 -14.08 5.81 12.28
2013-09-30 1.91 -16.53 5.34 11.63
2013-06-30 0.43 -15.30 4.57 11.57
2013-03-31 0.40 -12.88 4.36 10.08
2012-12-31 0.24 -13.63 4.14 9.44
2012-09-30 0.11 -12.61 2.86 8.69
2012-06-30 -12.70 4.24 8.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Compugen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Compugen has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Compugen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Compugen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Compugen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Compugen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Compugen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Compugen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Compugen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Compugen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Compugen has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Compugen Company Filings, last reported 4 months ago.

NasdaqGM:CGEN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 37.24 0.00 45.07
2018-09-30 38.17 0.00 34.90
2018-06-30 40.55 0.00 42.46
2018-03-31 30.41 0.00 20.53
2017-12-31 29.30 0.00 29.39
2017-09-30 38.00 0.00 38.46
2017-06-30 47.22 0.00 45.06
2017-03-31 55.77 0.00 54.49
2016-12-31 63.52 0.00 60.53
2016-09-30 70.35 0.00 68.10
2016-06-30 77.13 0.00 73.19
2016-03-31 82.89 0.00 81.54
2015-12-31 89.90 0.00 80.77
2015-09-30 89.41 0.00 75.20
2015-06-30 95.41 0.00 96.10
2015-03-31 100.96 0.00 66.75
2014-12-31 106.12 0.00 73.84
2014-09-30 106.32 0.00 108.84
2014-06-30 98.13 0.00 115.12
2014-03-31 99.95 0.00 120.72
2013-12-31 31.89 0.00 51.33
2013-09-30 27.03 0.00 47.82
2013-06-30 20.71 0.00 32.82
2013-03-31 21.76 0.00 29.51
2012-12-31 17.67 0.00 24.79
2012-09-30 18.69 0.00 20.06
2012-06-30 21.89 0.00 21.89
  • Compugen has no debt.
  • Compugen has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Compugen has sufficient cash runway for more than 3 years based on current free cash flow.
  • Compugen has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -10.7% each year.
X
Financial health checks
We assess Compugen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Compugen has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Compugen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Compugen dividends.
If you bought $2,000 of Compugen shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Compugen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Compugen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CGEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CGEN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Compugen has not reported any payouts.
  • Unable to verify if Compugen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Compugen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Compugen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Compugen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Compugen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Compugen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Compugen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anat Cohen-Dayag
COMPENSATION $854,003
AGE 51
TENURE AS CEO 9.2 years
CEO Bio

Dr. Anat Cohen-Dayag, Ph.D., has been the Chief Executive Officer at Compugen Ltd. since March 2010 and serves as its President since June 2009. Dr. Cohen-Dayag served as Vice President of Research & Development at Compugen Ltd. from November 2008 to March 2010 and its Co-Chief Executive Officer from June 2009 to March 2010. She served as Vice President of Diagnostic Biomarkers at Compugen Ltd. from January 1, 2006 to January 2007 and served as its Vice President of Diagnostic Biomarkers and Therapeutic/Drug Targets from January 2007 to November 2008. She joined Compugen in 2002 where she served as Director of Diagnostics since 2005. Prior to joining Compugen, she served as Head of Research and Development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems, she served as a scientist at the R&D department of Orgenic. She has been Director of Compugen Ltd. since February 10, 2014. She serves as a Director of Ramot at Tel Aviv University Ltd. She serves as Director at Ramot at Tel Aviv University Ltd., Investment Arm. She holds a B.Sc. in Biology from Ben-Gurion University and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.

CEO Compensation
  • Anat's compensation has increased whilst company is loss making.
  • Anat's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Compugen management team in years:

2.4
Average Tenure
50.5
Average Age
  • The tenure for the Compugen management team is about average.
Management Team

Anat Cohen-Dayag

TITLE
CEO, President & Director
COMPENSATION
$854K
AGE
51
TENURE
9.2 yrs

Ari Krashin

TITLE
Chief Financial & Operating Officer
COMPENSATION
$576K
AGE
45
TENURE
4.7 yrs

John Hunter

TITLE
Chief Scientific Officer
COMPENSATION
$603K
AGE
55
TENURE
0.6 yrs

Kirk Christoffersen

TITLE
Senior Vice President of Corporate & Business Development
COMPENSATION
$639K
AGE
49
TENURE
2.4 yrs

Henry Adewoye

TITLE
Chief Medical Officer
COMPENSATION
$613K
TENURE
1.2 yrs

Elana Holzman

TITLE
Director of Investor Relations & Corporate Communications

Donna Gershowitz

TITLE
General Counsel
AGE
54

Dorit Amitay

TITLE
Vice President of Human Resources
AGE
50
TENURE
12.3 yrs

Zurit Levine

TITLE
Senior Vice President of Technology Innovation
COMPENSATION
$356K
AGE
50

Martin Gerstel

TITLE
Senior Advisor
AGE
77
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Compugen board of directors in years:

5.8
Average Tenure
61
Average Age
  • The tenure for the Compugen board of directors is about average.
Board of Directors

Paul Sekhri

TITLE
Chairman
AGE
60
TENURE
1.6 yrs

Anat Cohen-Dayag

TITLE
CEO, President & Director
COMPENSATION
$854K
AGE
51
TENURE
5.3 yrs

Arie Ovadia

TITLE
External Director
AGE
70
TENURE
11.8 yrs

Drew Pardoll

TITLE
Chairman of Scientific Advisory Board

Sandy Zweifach

TITLE
Director
AGE
62
TENURE
0.9 yrs

Kinneret Savitzky

TITLE
Director
AGE
51
TENURE
0.9 yrs

Yair Aharonowitz

TITLE
External Director
AGE
77
TENURE
11.8 yrs

Charles Drake

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs

Iain McInnes

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs

Toni Ribas

TITLE
Member of Scientific Advisory Board
TENURE
5.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Compugen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Compugen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Introducing Compugen, The Stock That Tanked 73%

Compugen isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't yet make profits, we'd generally expect to see good revenue growth. … Over five years, Compugen grew its revenue at 6.4% per year.

Simply Wall St -

Introducing Compugen, The Stock That Tanked 73%

Compugen isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't yet make profits, we'd generally expect to see good revenue growth. … Over five years, Compugen grew its revenue at 6.4% per year.

Simply Wall St -

Should You Worry About Compugen Ltd's (NASDAQ:CGEN) CEO Pay?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … CEOs leading companies of similar size and profitability

Simply Wall St -

Did Compugen Ltd's (NASDAQ:CGEN) Recent Earnings Growth Beat The Trend?

When Compugen Ltd (NASDAQ:CGEN) released its most recent earnings update (31 March 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … CGEN is loss-making, with the most recent trailing twelve-month earnings of -US$28.25m (from 31 March 2018), which compared to last year has become. … However, the company's loss seem to be contracting over the medium term, with the five-year earnings average of -US$19.05m

Simply Wall St -

Should You Buy Compugen Ltd (NASDAQ:CGEN)?

This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. … NasdaqGM:CGEN Future Profit May 2nd 18 Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations.

Simply Wall St -

Was Compugen Ltd's (NASDAQ:CGEN) Earnings Decline Part Of A Broader Industry Downturn?

To account for any quarterly or half-yearly updates, I use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … For Compugen, its latest earnings (trailing twelve month) is -US$37.07M, which, against the prior year's level, has become more negative. … The most insightful step is to assess company-specific issues Compugen may be facing and whether management guidance has consistently been met in the past.

Simply Wall St -

Compugen Ltd (NASDAQ:CGEN): Earnings Expected To Remain Subdued

Compugen Ltd's (NASDAQ:CGEN) most recent earnings update in December 2017 revealed company earnings became less negative compared to the previous year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts view Compugen's earnings growth trajectory over the next few years and whether the future looks brighter. … NasdaqGM:CGEN Future Profit Apr 5th 18 Although it is helpful to be aware of the growth each year relative to today’s level, it may be more insightful gauging the rate at which the company is rising or falling on average every year. … Future Earnings: How does CGEN's growth rate compare to its peers and the wider market?

Simply Wall St -

Why Compugen Ltd's (NASDAQ:CGEN) CEO Pay Check Matters To You

Therefore I will use earnings as a proxy of Cohen-Dayag's performance in the past year. … Most recently, CGEN delivered negative earnings of -US$36.25M , which is a further decline from prior year's loss of -US$23.49M. … Typically I'd use market cap and profit as factors determining performance, however, CGEN's negative earnings lower the effectiveness of this method.

Simply Wall St -

Should You Be Concerned About Compugen Ltd's (NASDAQ:CGEN) Risks?

Not every stock is exposed to the same level of market risk. … CGEN’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … CGEN, with its market capitalisation of $166.22M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Should Compugen Ltd's (NASDAQ:CGEN) Recent Earnings Decline Worry You?

After reading Compugen Ltd's (NASDAQ:CGEN) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … See our latest analysis for Compugen Did CGEN perform worse than its track record and industry? … I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Company Info

Description

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Details
Name: Compugen Ltd.
CGEN
Exchange: NasdaqGM
Founded: 1993
$207,261,515
59,902,172
Website: http://www.cgen.com
Address: Compugen Ltd.
Building D,
26 Harokmim Street,
Holon,
5885849,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CGEN Ordinary Shares Nasdaq Global Market US USD 11. Aug 2000
DB CW9 Ordinary Shares Deutsche Boerse AG DE EUR 11. Aug 2000
TASE CGEN Ordinary Shares The Tel-Aviv Stock Exchange IL ILS 11. Aug 2000
Number of employees
Current staff
Staff numbers
89
Compugen employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:45
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/02/27
Last earnings filing: 2019/03/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.